In the current global market landscape, the S&P 500 Index has seen advances driven by sectors such as utilities and real estate, while small-cap indices like the Russell 2000 have shown notable outperformance. Amidst this backdrop of fluctuating oil prices and renewed interest in AI-related stocks, identifying growth companies with strong insider ownership can be a strategic approach for investors looking to align with businesses that demonstrate both potential for expansion and a vested interest from those who know them best.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3) | 11.9% | 21.1% |
| Atlas Energy Solutions (NYSE:AESI) | 29.1% | 41.9% |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 27.4% |
| People & Technology (KOSDAQ:A137400) | 16.4% | 35.6% |
| KebNi (OM:KEBNI B) | 36.3% | 86.1% |
| Findi (ASX:FND) | 35.8% | 64.8% |
| HANA Micron (KOSDAQ:A067310) | 18.3% | 105.8% |
| Credo Technology Group Holding (NasdaqGS:CRDO) | 13.9% | 95% |
| Adveritas (ASX:AV1) | 21.2% | 144.2% |
| Plenti Group (ASX:PLT) | 12.8% | 107.6% |
Here's a peek at a few of the choices from the screener.
Zhejiang Starry PharmaceuticalLtd (SHSE:603520)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Zhejiang Starry Pharmaceutical Co., Ltd. is involved in the research, development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates both in China and internationally, with a market cap of CN¥3.99 billion.
Operations: The company generates revenue through the development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in both domestic and international markets.
Insider Ownership: 25.9%
Earnings Growth Forecast: 78.5% p.a.
Zhejiang Starry Pharmaceutical Ltd. shows potential as a growth company with high insider ownership, highlighted by recent acquisitions of significant stakes by private funds. Despite past shareholder dilution and low dividend coverage, the company is expected to see substantial revenue growth at 20.3% annually, outpacing the market average. Earnings are forecasted to grow significantly at 78.5% per year, though interest payments remain poorly covered by earnings and return on equity is projected to be modest.
- Click here and access our complete growth analysis report to understand the dynamics of Zhejiang Starry PharmaceuticalLtd.
- Upon reviewing our latest valuation report, Zhejiang Starry PharmaceuticalLtd's share price might be too optimistic.
Suzhou Delphi Laser (SHSE:688170)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Suzhou Delphi Laser Co., Ltd. is involved in the research, development, manufacture, and sale of precision laser processing equipment and lasers both in China and internationally, with a market cap of CN¥2.63 billion.
Operations: Suzhou Delphi Laser Co., Ltd. generates revenue through its precision laser processing equipment and lasers, catering to both domestic and international markets.
Insider Ownership: 28.2%
Earnings Growth Forecast: 45.9% p.a.
Suzhou Delphi Laser's earnings are forecasted to grow significantly at 45.88% annually, outpacing the Chinese market. Despite this, the company reported a net loss of CNY 9.87 million for the first half of 2024, with profit margins declining from last year. Revenue is expected to grow at 17.8% per year, faster than the market average but below desired levels for high-growth companies. The dividend yield of 1.17% is not well covered by earnings or cash flows.
- Dive into the specifics of Suzhou Delphi Laser here with our thorough growth forecast report.
- In light of our recent valuation report, it seems possible that Suzhou Delphi Laser is trading beyond its estimated value.
Hubei Huitian New Materials (SZSE:300041)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Hubei Huitian New Materials Co., Ltd. is involved in the research, development, manufacturing, and sale of adhesives and new materials both in China and internationally, with a market capitalization of CN¥4.85 billion.
Operations: Hubei Huitian New Materials Co., Ltd. generates revenue through its activities in the research, development, production, and distribution of adhesives and new materials across domestic and international markets.
Insider Ownership: 21.1%
Earnings Growth Forecast: 25.1% p.a.
Hubei Huitian New Materials is forecasted to achieve significant earnings growth at 25.1% annually, surpassing the Chinese market average. However, recent financial results show a decline in net income to CNY 136.8 million for the first half of 2024, with profit margins dropping to 5.5%. Despite trading well below estimated fair value, insider trading activity has been minimal recently. Revenue growth is expected at 13.6% per year, slightly above market rates but not exceptionally high for growth companies.
- Click here to discover the nuances of Hubei Huitian New Materials with our detailed analytical future growth report.
- Our valuation report here indicates Hubei Huitian New Materials may be undervalued.
Where To Now?
- Discover the full array of 1487 Fast Growing Companies With High Insider Ownership right here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Hubei Huitian New Materials might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SZSE:300041
Hubei Huitian New Materials
Researches, develops, manufactures, and sells adhesives and new materials in China and internationally.
Excellent balance sheet with reasonable growth potential and pays a dividend.
